Biological/Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, Japan.
Physiol Res. 2021 Mar 17;70(1):45-54. doi: 10.33549/physiolres.934533. Epub 2021 Jan 14.
Glomerular hyperfiltration is observed in an early stage of kidney diseases including diabetic nephropathy. A better understanding of pathophysiological changes in glomerular hyperfiltration is essential for development of new therapies to prevent kidney disease progression. In this study, we investigated glomerular changes including glomerular filtration rate (GFR) and glomerular size in the Spontaneously Diabetic Torii (SDT) fatty rat, an obese type 2 diabetic model, and we also evaluated pharmacological effects of the sodium glucose cotransporter 2 inhibitor dapagliflozin on the renal lesions. Dapagliflozin was administered to SDT fatty rats from 5 to 17 weeks of age. Blood and urinary biochemical parameters were periodically measured. GFR was determined by transdermal GFR monitor at 16 weeks of age and histopathological analysis was performed at 17 weeks of age. SDT fatty rat developed severe hyperglycemia and exhibited pathophysiological abnormalities in the kidney, such as an increased GFR, glomerular hypertrophy and tissue lesions. Dapagliflozin achieved good glycemic control during the experimental period, inhibited the increase in GFR, and improved histopathological abnormalities in tubules. These results suggest that the SDT fatty rat is a useful model for analyzing the pathogenesis of diabetic nephropathy during its early stage and dapagliflozin improves not only hyperglycemia but also glomerular hyperfiltration and tubule lesions in SDT fatty rat.
肾小球高滤过发生于糖尿病肾病等多种肾脏疾病的早期。深入了解肾小球高滤过的病理生理学改变,对于开发预防肾脏疾病进展的新疗法至关重要。在这项研究中,我们观察了肥胖 2 型糖尿病模型 Spontaneously Diabetic Torii (SDT) 肥胖大鼠的肾小球改变,包括肾小球滤过率(GFR)和肾小球大小,并评估了钠-葡萄糖协同转运蛋白 2 抑制剂达格列净对肾脏病变的药理作用。从 5 至 17 周龄时,达格列净被给予 SDT 肥胖大鼠。定期测量血液和尿液生化参数。在 16 周龄时,通过经皮 GFR 监测仪确定 GFR,并在 17 周龄时进行组织病理学分析。SDT 肥胖大鼠出现严重高血糖,并表现出肾脏的病理生理异常,如 GFR 增加、肾小球肥大和组织病变。在实验期间,达格列净实现了良好的血糖控制,抑制了 GFR 的增加,并改善了肾小管的组织病理学异常。这些结果表明,SDT 肥胖大鼠是分析早期糖尿病肾病发病机制的有用模型,达格列净不仅改善了高血糖,还改善了 SDT 肥胖大鼠的肾小球高滤过和肾小管病变。